Completed PHASE1 INTERVENTIONAL NCT00744887
TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.
Phase I, Open-label, Randomized, 3-way Crossover Trial to Assess the Pharmacokinetics of Darunavir (DRV) Given Once-daily With Different Doses of Ritonavir in Healthy Subjects.
Sponsor: Tibotec Pharmaceuticals, Ireland
Interventions
Darunavir
Updated 1 time since 2024 Last updated: Jun 8, 2011 Started: Aug 31, 2008 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT00744887, this PHASE1 trial focuses on AIDS and HIV and remains completed. Sponsored by Tibotec Pharmaceuticals, Ireland, it has been updated 1 time since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
1 version recorded Completed — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Tibotec Pharmaceuticals, Ireland
Data source: Tibotec Pharmaceuticals, Ireland
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.